NASDAQ:EVOK - Evoke Pharma Stock Price Target and Predictions

  • Consensus Rating: N/A
  • Consensus Price Target: $0.00
  • Forecasted Upside: -100.00 %
  • Number of Analysts: 0
  • Breakdown:
  • 0 Sell Ratings
  • 0 Hold Ratings
  • 0 Buy Ratings
  • 0 Strong Buy Ratings
$1.35
▲ +0.06 (4.65%)

This chart shows the closing price for EVOK by one month, three months, or twelve months.

Skip Closing Price Chart
1 month | 3 months | 12 months
Get New Evoke Pharma Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for EVOK and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for EVOK

Analyst Price Target is $0.00
▼ -100.00% Downside Potential
This price target is based on 0 analysts offering 12 month price targets for Evoke Pharma in the last 3 months. The average price target is $0.00, with a high forecast of $0.00 and a low forecast of $10,000,000.00. The average price target represents a -100.00% upside from the last price of $1.35.

This chart shows the closing price for EVOK for the last year in relation to the current analyst high, average, and low pricetarget.

Read Analyst Price Chart DescriptionSkip Analyst Price Chart

Current Consensus is N/A

The current consensus among 0 investment analysts is to n/a stock in Evoke Pharma. This rating has held steady since July 2021, when it changed from a Buy consensus rating.

Past Monthly Recommendations

Move your mouse over past months for details

Read Past Recommendations DescriptionSkip Past Price Target Consensus Chart
  • 0 strong buy ratings
  • 1 buy ratings
  • 0 hold ratings
  • 0 sell ratings
4/4/2020
  • 0 strong buy ratings
  • 1 buy ratings
  • 0 hold ratings
  • 0 sell ratings
7/3/2020
  • 0 strong buy ratings
  • 1 buy ratings
  • 0 hold ratings
  • 0 sell ratings
10/1/2020
  • 0 strong buy ratings
  • 1 buy ratings
  • 0 hold ratings
  • 0 sell ratings
12/30/2020
  • 0 strong buy ratings
  • 1 buy ratings
  • 0 hold ratings
  • 0 sell ratings
3/30/2021
  • 0 strong buy ratings
  • 1 buy ratings
  • 0 hold ratings
  • 0 sell ratings
6/28/2021
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
8/27/2021
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
9/26/2021

Latest Recommendations

  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
8/10/2020HC WainwrightReiterated RatingBuy$10.00High
7/17/2020HC WainwrightReiterated RatingBuy$10.00Low
6/22/2020HC WainwrightUpgradeNeutral ➝ Buy$10.00High
5/21/2020HC WainwrightReiterated RatingHoldMedium
1/28/2020HC WainwrightReiterated RatingHoldLow
12/2/2019HC WainwrightReiterated RatingHoldHigh
8/9/2019HC WainwrightReiterated RatingHoldMedium
6/28/2019HC WainwrightReiterated RatingHoldLow
5/28/2019HC WainwrightReiterated RatingHoldHigh
3/5/2019HC WainwrightDowngradeBuy ➝ Neutral$1.33High
3/4/2019B. RileySet Price TargetBuy$5.00High
12/10/2018HC WainwrightSet Price TargetBuy$9.00Medium
11/14/2018B. RileyReiterated RatingBuyHigh
8/17/2018HC WainwrightSet Price TargetBuy$9.00Medium
6/5/2018HC WainwrightSet Price TargetBuy$9.00High
5/3/2018HC WainwrightSet Price TargetBuy$9.00Low
4/2/2018HC WainwrightSet Price TargetBuy$9.00Medium
3/8/2018B. RileyReiterated RatingBuy ➝ Buy$10.00 ➝ $5.00Medium
3/6/2018HC WainwrightReiterated RatingBuy$9.00Low
11/29/2017HC WainwrightSet Price TargetBuy$9.00Medium
11/15/2017B. RileyReiterated RatingBuy$10.00N/A
10/30/2017FBR & Co.Reiterated RatingBuy$10.00N/A
10/24/2017HC WainwrightReiterated RatingBuy$9.00N/A
10/19/2017FBR & Co.Reiterated RatingBuy ➝ Buy$10.00N/A
10/18/2017Northland SecuritiesReiterated RatingBuy$10.00N/A
10/6/2017Seaport Global SecuritiesReiterated RatingBuy$10.00N/A
9/18/2017HC WainwrightReiterated RatingBuy$9.00Low
8/15/2017HC WainwrightReiterated RatingBuy$9.00Low
5/18/2017FBR & Co.Reiterated RatingBuy$9.00Low
3/16/2017HC WainwrightSet Price TargetBuy$9.00Medium
3/16/2017Ascendiant Capital MarketsBoost Price TargetIn-Line$5.00 ➝ $6.00High
3/16/2017Rodman & RenshawReiterated RatingBuy ➝ Buy$6.00 ➝ $9.00High
1/31/2017FBR & Co.Reiterated RatingOutperform ➝ Positive$9.00N/A
1/30/2017LaidlawUpgradeNeutral ➝ Buy$8.00N/A
1/6/2017FBR & Co.Reiterated RatingOutperform$9.00N/A
1/5/2017Rodman & RenshawUpgradeNeutral ➝ Buy$2.50 ➝ $6.00N/A
1/5/2017HC WainwrightUpgradeNeutral ➝ BuyN/A
12/31/2016Rodman & RenshawBoost Price TargetNeutral$2.00 ➝ $2.50N/A
12/25/2016HC WainwrightSet Price TargetHold$3.00N/A
12/23/2016Rodman & RenshawBoost Price TargetNeutral$2.00 ➝ $2.50N/A
12/21/2016FBR & Co.Reiterated RatingOutperform$9.00N/A
11/18/2016FBR & Co.Reiterated RatingOutperform$9.00N/A
(Data available from 9/27/2016 forward)

News Sentiment Rating

0.20 (Hold)

Our news sentiment rating is based on the average sentiment of articles about this company published in the media in the last 30 days of headlines and can range from 2 (very positive sentiment) to -2 (very negative sentiment).

News Sentiment Over Time

Move your mouse over past months for details

Skip to Current Sentiment Summary
  • 1 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
3/1/2021
  • 0 very positive mentions
  • 1 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
3/31/2021
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
4/30/2021
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
5/30/2021
  • 0 very positive mentions
  • 1 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
6/29/2021
  • 2 very positive mentions
  • 1 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
7/29/2021
  • 2 very positive mentions
  • 3 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
8/28/2021
  • 1 very positive mentions
  • 2 positive mentions
  • 1 negative mentions
  • 1 very negative mentions
9/27/2021

Current Sentiment

  • 1 very positive mentions
  • 2 positive mentions
  • 1 negative mentions
  • 1 very negative mentions
Evoke Pharma logo
Evoke Pharma, Inc. is a pharmaceutical company, which engages in the development of drugs for the treatment of gastrointestinal disorders and diseases. It develops Gimoti, with promotility and anti-emetic effects, for the relief of symptoms associated with acute and recurrent diabetic gastroparesis in women with diabetes mellitus. The company was founded by Matthew J. D'Onofrio, Cam L. Garner, Scott L. Glenn, and David A. Gonyer in January 2007 and is headquartered in Solana Beach, CA.
Read More

Today's Range

Now: $1.35
Low: $1.24
High: $1.35

50 Day Range

MA: $1.14
Low: $1.04
High: $1.35

52 Week Range

Now: $1.35
Low: $0.96
High: $5.00

Volume

148,100 shs

Average Volume

561,520 shs

Market Capitalization

$43.79 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

1.2

Frequently Asked Questions

What sell-side analysts currently cover shares of Evoke Pharma?

The following Wall Street sell-side analysts have issued research reports on Evoke Pharma in the last year: Zacks Investment Research.
View the latest analyst ratings for EVOK.

What is the current price target for Evoke Pharma?

0 Wall Street analysts have set twelve-month price targets for Evoke Pharma in the last year. has the lowest price target set, forecasting a price of $10,000,000.00 for Evoke Pharma in the next year.
View the latest price targets for EVOK.

What is the current consensus analyst rating for Evoke Pharma?

Evoke Pharma currently has from Wall Street analysts. The stock has a consensus analyst rating of "N/A."
View the latest ratings for EVOK.

How do I contact Evoke Pharma's investor relations team?

Evoke Pharma's physical mailing address is 420 STEVENS AVENUE SUITE 370, SOLANA BEACH CA, 92075. The specialty pharmaceutical company's listed phone number is (858) 345-1494 and its investor relations email address is [email protected] The official website for Evoke Pharma is www.evokepharma.com.